Your session is about to expire
← Back to Search
Exercise Program for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients (B-HAPI Trial)
B-HAPI Trial Summary
This trial will test the effects of a 16 week gait/balance training plus resistance exercise program to address persistent taxane-induced peripheral neuropathy in 312 patients treated for breast cancer.
B-HAPI Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowB-HAPI Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.B-HAPI Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am a woman over 21 who finished treatment for breast cancer with taxane-based chemotherapy.I have swelling due to lymphedema or my condition puts me at high risk for bone issues.I have a condition like diabetes or HIV that causes nerve damage or muscle weakness.I do not have any health conditions that prevent me from exercising.My nerve pain score is over 3, similar to severe diabetic nerve pain.
- Group 1: Intervention Group
- Group 2: Attention Control Group
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the limit of participants in this clinical trial?
"Affirmative. Clinicaltrials.gov data highlights that this study, first published on August 14th 2020, is actively recruiting participants. The trial requires 312 volunteers from a single medical facility to participate."
What results is the research team hoping to achieve with this trial?
"This trial's primary goal is to observe any changes over the course of 16 weeks. Secondary endpoints include monitoring a participant's Body Mass Index, which will be measured using Tanita body composition analyzers; tracking medications used for neuropathic pain and documenting dosage change/no change; and assessing severity of pain, its impact on daily life, location of pain etc., via Brief Pain Inventory."
Is this investigation looking to enroll new participants?
"Affirmative, the research posted on clinicaltrials.gov implies that this trial is actively accepting participants. After being initially shared on August 14th 2020 and updated most recently on November 5th 2020, 312 recruits are still needed from a singular site."
Share this study with friends
Copy Link
Messenger